Cancer/testis antigen 1 (53-62)

Cancer/testis antigen 1 (53-62) is a synthetic peptide fragment derived from the immunodominant region of the cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1. As a member of the cancer/testis antigen family, this peptide is characterized by its restricted expression pattern—typically limited to germ cells of the testis and aberrantly activated in a variety of malignancies. The 53-62 sequence represents a well-defined epitope recognized by cytotoxic T lymphocytes, making it a valuable tool for immunological studies focused on tumor antigens. Its precise sequence and immunogenic properties have established it as a model system for investigating antigen presentation, immune recognition, and peptide-based immunological assays.

Epitope mapping: Researchers utilize the 53-62 peptide fragment in epitope mapping studies to delineate the specific regions of CTAG1 recognized by T cells. By exposing immune effector cells to this defined peptide, investigators can systematically analyze T cell responses, helping to identify immunodominant epitopes and understand the molecular basis of tumor antigen recognition. Such mapping is essential for the rational design of immunotherapeutic strategies and for gaining insight into the specificity of anti-tumor immune responses.

T cell activation assays: The peptide serves as a standard reagent in T cell activation and proliferation assays. When presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells, it can stimulate antigen-specific cytotoxic T lymphocytes in vitro. These assays are instrumental for evaluating T cell functionality, studying antigen processing and presentation pathways, and optimizing conditions for immune monitoring in cancer research settings. The ability of the 53-62 epitope to elicit robust T cell responses makes it a preferred choice for such immunological assessments.

Peptide-MHC binding studies: The defined sequence of Cancer/testis antigen 1 (53-62) enables its use in quantitative and qualitative analyses of peptide-MHC interactions. Researchers employ this peptide to investigate binding affinities, stability, and presentation dynamics on various MHC class I molecules. These studies provide critical insights into the molecular determinants of antigen presentation, contributing to fundamental immunology research and informing the selection of target epitopes for further immunotherapeutic development.

Synthetic peptide library development: The 53-62 fragment is frequently incorporated into synthetic peptide libraries for high-throughput screening applications. Its inclusion allows for the evaluation of cross-reactivity, antigen mimicry, and the identification of T cell receptor (TCR) repertoires with specificity for CTAG1-derived epitopes. Such libraries are crucial for dissecting immune landscapes, profiling antigen-specific responses, and advancing peptide-based research methodologies in oncology and immunology.

Immunoassay calibration: The peptide is often employed as a positive control or standard in various immunoassays, including enzyme-linked immunospot (ELISPOT), enzyme-linked immunosorbent assay (ELISA), and flow cytometry-based detection of antigen-specific T cells. By providing a consistent and well-characterized antigenic stimulus, it supports assay validation, reproducibility, and quantitative comparison across experimental runs. This application is particularly valuable in translational research, where reproducible measurement of immune responses to tumor antigens is essential for both basic and applied scientific investigations.

1. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

2. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

3. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate

4. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists